Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Boehringer Ingelheim
Merck
Baxter
Moodys

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 9,683,047

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,683,047
Title:Methods for treating progressive multiple sclerosis
Abstract: The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.
Inventor(s): Smith; Craig (Seattle, WA), Chin; Peter S. (San Francisco, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Application Number:15/201,300
Patent Claims:1. A method of treating multiple sclerosis in a patient comprising administering an effective amount of ocrelizumab to the patient to provide an initial ocrelizumab exposure of between about 0.3 to about 0.6 grams followed by a second ocrelizumab exposure of between about 0.3 to about 0.6 grams, the second exposure not being provided until from about 16 to 60 weeks from the initial exposure, and each of the ocrelizumab exposures is provided to the patient as one or two doses of ocrelizumab.

2. The method of claim 1, wherein the initial ocrelizumab exposure comprises a first dose and a second dose of ocrelizumab, wherein the first dose and second dose of ocrelizumab is about 0.3 grams.

3. The method of claim 2, wherein the second dose is administered from about 3 to 17 days from the time the first dose was administered.

4. The method of claim 2, wherein the second dose is administered from about 6 to 16 days from the time the first dose was administered.

5. The method of claim 2, wherein the second dose is administered from about 13 to 16 days from the time the first dose was administered.

6. The method of claim 2, wherein the second dose is administered 15 days from the time the first dose was administered.

7. The method of claim 2, wherein the second ocrelizumab exposure comprises a single dose of ocrelizumab, wherein the single dose of ocrelizumab is 0.6 grams.

8. The method of claim 7, wherein the second ocrelizumab exposure is provided approximately 24 weeks after the initial ocrelizumab exposure.

9. The method of claim 8, further comprising providing a third ocrelizumab exposure.

10. The method of claim 9, wherein the third ocrelizumab exposure is provided approximately 46 to 60 weeks from the initial exposure.

11. The method of claim 9, wherein the third ocrelizumab exposure is provided approximately 46 to 54 weeks from the initial exposure.

12. The method of claim 9, further comprising providing a fourth ocrelizumab exposure.

13. The method of claim 12, further comprising providing a fifth ocrelizumab exposure.

14. The method of claim 8, further comprising providing between about one to about three subsequent ocrelizumab exposures.

15. The method of claim 1, wherein a second medicament is administered with the initial exposure or later exposures, wherein the ocrelizumab is the first medicament.

16. The method of claim 15, wherein the second medicament is selected from the group consisting of an interferon, glatiramer acetate, a cytotoxic agent, a chemotherapeutic agent, mitoxantrone, methotrexate, cyclophosphamide, chlorambucil, azathioprine, gamma globulin, Campath, anti-CD4, cladribine, corticosteroid, mycophenolate mofetil (MMF), cyclosporine, a cholesterol-lowering drug of the statin class, estradiol, testosterone; a hormone replacement drug, a TNF inhibitor, a disease-modifying anti-rheumatic drug (DMARD), a non-steroidal anti-inflammatory drug (NSAID), levothyroxine, cyclosporin A, a somatastatin analogue, a cytokine or cytokine receptor antagonist, an anti-metabolite, an immunosuppressive agent, an integrin antagonist or antibody, an LFA-1 antibody, efalizumab, an alpha 4 integrin antibody, natalizumab, and another B-cell surface marker antibody.

17. The method of claim 1, wherein the multiple sclerosis is primary progressive multiple sclerosis (PPMS).

18. The method of claim 1, wherein the multiple sclerosis is relapsing remitting multiple sclerosis (RRMS).

19. The method of claim 1, wherein the subject has never been previously treated with an anti-CD20 antibody.

20. The method of claim 1, wherein the ocrelizumab is a naked antibody.

21. The method of claim 1, wherein the ocrelizumab is conjugated to another molecule.

22. The method of claim 21, wherein the other molecule is a cytotoxic agent.

23. The method of claim 1, wherein the ocrelizumab is administered intravenously.

24. The method of claim 1, wherein the ocrelizumab is administered subcutaneously.

25. The method of claim 1, wherein the ocrelizumab is administered intrathecally.

26. The method of claim 1, wherein ocrelizumab is the only medicament administered to the subject to treat multiple sclerosis.

27. The method of claim 1, wherein the subject has elevated anti-myelin basic protein (MBP), anti-myelin oligodendrocytic glycoprotein (MOG), anti-ganglioside and/or anti-neurofilament antibody levels.

28. The method of claim 1, wherein elevated levels of B cells are present in cerebrospinal fluid (CSF), multiple sclerosis lesion, or serum of the subject.

29. An article of manufacture comprising: (a) a container comprising ocrelizumab; and (b) a package insert with instructions for treating multiple sclerosis in a patient, wherein the instructions indicate that an amount of ocrelizumab is administered to the patient that is effective to provide an initial ocrelizumab exposure of between about 0.3 to about 0.6 grams followed by a second ocrelizumab exposure of between about 0.3 to about 0.6 grams, the second exposure not being administered until from about 16 to 60 weeks from the initial exposure, and each of the ocrelizumab exposures is provided to the patient as one or two doses of ocrelizumab.

Details for Patent 9,683,047

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 2001-05-07 ⤷  Try it Free 2028-09-16
Genzyme Corporation LEMTRADA alemtuzumab Injection 103948 2014-11-14 ⤷  Try it Free 2028-09-16
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 2004-10-12 ⤷  Try it Free 2028-09-16
Genentech, Inc. RAPTIVA efalizumab Injection 125075 2003-10-27 ⤷  Try it Free 2028-09-16
Biogen Inc. TYSABRI natalizumab Injection 125104 2004-11-23 ⤷  Try it Free 2028-09-16
Genentech, Inc. OCREVUS ocrelizumab Injection 761053 2017-03-28 ⤷  Try it Free 2028-09-16
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Baxter
Johnson and Johnson
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.